Nevro Quick Ratio 2013-2022 | NVRO

Historical quick ratio values for Nevro (NVRO) over the last 10 years.
Nevro Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-09-30 $0.47B $0.08B 5.82
2022-06-30 $0.39B $0.07B 5.36
2022-03-31 $0.40B $0.07B 5.69
2021-12-31 $0.44B $0.08B 5.32
2021-09-30 $0.45B $0.08B 5.97
2021-06-30 $0.47B $0.07B 6.37
2021-03-31 $0.65B $0.25B 2.65
2020-12-31 $0.67B $0.24B 2.80
2020-09-30 $0.66B $0.24B 2.75
2020-06-30 $0.63B $0.22B 2.83
2020-03-31 $0.32B $0.06B 5.26
2019-12-31 $0.33B $0.07B 4.68
2019-09-30 $0.31B $0.07B 4.54
2019-06-30 $0.31B $0.07B 4.66
2019-03-31 $0.32B $0.07B 4.87
2018-12-31 $0.35B $0.06B 5.64
2018-09-30 $0.34B $0.05B 6.31
2018-06-30 $0.34B $0.05B 6.29
2018-03-31 $0.33B $0.05B 6.17
2017-12-31 $0.34B $0.06B 5.91
2017-09-30 $0.33B $0.05B 6.81
2017-06-30 $0.32B $0.04B 8.72
2017-03-31 $0.32B $0.03B 9.43
2016-12-31 $0.34B $0.04B 7.94
2016-09-30 $0.34B $0.04B 9.71
2016-06-30 $0.33B $0.03B 10.94
2016-03-31 $0.20B $0.03B 7.82
2015-12-31 $0.22B $0.04B 6.05
2015-09-30 $0.24B $0.02B 10.07
2015-06-30 $0.27B $0.02B 16.53
2015-03-31 $0.17B $0.01B 12.63
2014-12-31 $0.19B $0.01B 17.25
2014-09-30 $0.04B $0.01B 4.76
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B 0.00
2012-12-31 $0.04B $0.01B 7.49
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.556B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.645B 22.45
Edwards Lifesciences (EW) United States $46.932B 32.30
Alcon (ALC) Switzerland $33.321B 28.69
STERIS (STE) Ireland $18.019B 22.42
Teleflex (TFX) United States $10.587B 17.18
Fresenius Medical Care AG KGaA (FMS) Germany $8.996B 9.03
Penumbra (PEN) United States $7.452B 1783.82
Globus Medical (GMED) United States $7.103B 36.11
Integer Holdings (ITGR) United States $2.367B 19.00
Glaukos (GKOS) United States $2.263B 0.00
Paragon 28 (FNA) United States $1.534B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.246B 17.74
Artivion (AORT) United States $0.520B 0.00